Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
Go back to Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 64.69 -2.13 (3.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $66.82 | 52 Week High | $77.12 | |||
| Open | $65.66 | 52 Week Low | $49.03 | |||
| Day High | $65.89 | P/E | 42.01 | |||
| Day Low | $64.40 | EPS | $1.54 | |||
| Volume | 9,524,638 | |||||
